Emerging Treatments in HIV
Once-daily regimens have been shown to improve adherence to treatment with no adverse effect on outcomes in patients with HIV.
Primary study end point was noninferiority of the single-tablet regimen vs control, related to virologic rebound, cumulative through week 48.
Phase 3 study assessed efficacy and safety of switching to bictegravir/emtricitabine/tenofovir alafenamide from a multi-tablet regimen containing a boosted protease inhibitor regimen in virologically suppressed patients with HIV.
Virological response, efficacy, noninferiority, and tolerability were tested for bictegravir, emtricitabine, and tenofovir alafenamide vs dolutegravir, abacavir, and lamivudine.
The FDA has granted Priority Review to the New Drug Application for Gilead's investigational single-tablet regimen in the treatment of HIV-1 infection.
One-week amphotericin plus flucytosine was found to have comparable efficacy and safety profiles as the standard of care, 2-weeks amphotericin-based therapy, for treatment of HIV-associated cryptococcal meningitis in African patients.
The combination of long-acting intramuscular cabotegravir plus rilpivirine was demonstrated to be as effective as 3-drug daily oral ART for maintaining viral suppression of HIV-1 for up to 96 weeks in the LATTE-2 phase 2b study.
Gilead announced results from 2 Phase 3 studies for the investigational fixed-dose HIV regimen with bictegravir and emtricitabine for the treatment of treatment-naive adults with HIV.
Gilead submitted their single-tablet regimen containing bictegravir, emtricitabine, and tenofovir alafenamide for HIV-1 treatment to the FDA.
Pitavastatin reduced low-density lipoprotein cholesterol to a greater extent than pravastatin with a similar safety profile in patients with HIV and dyslipidemia.
Dual combination ART with atazanavir/ritonavir plus lamivudine demonstrated similar efficacy and safety as atazanavir/ritonavir plus 2 NRTIs at 48 weeks in the ATLAS-M trial.
Switching to TAF-based regimen was non-inferior to continuing TDF-based regimen in maintaining viral suppression.
Investigational combination of a once-daily 2-drug regimen of dolutegravir plus rilpivirine may be as effective as a 3- or 4-drug current antiretroviral regimen in HIV-1-infected patients.
Viral loads can fluctuate over time depending on patients' access and response to HIV treatment, their medication adherence behavior, and care status.
The once-daily dosing doravirine appears to have similar efficacy and to be non-inferior to once-daily ritonavir-boosted darunavir (DRV+r) on a background of 2 NRTIs in HIV-1 treatment-naïve adults.
New phase 3 results were reported from a single arm, multicenter study evaluating the safety and effectiveness of ibalizumab in patients infected with multidrug-resistant HIV-1.
HIV PEP preferred regimen Stribild seems to be a good option for immunocompetent people without HIV infection due to the ease of use and tolerable adverse effect profile.
Cancer prevention efforts for patients with HIV should focus on smoking cessation and appropriate screening based on recommendations for the general population.
Reduction in number of daily pills from 2005 to 2012; only 50.9% on BID regimen in 2012.
Reaching this target would see 90% of people living with HIV knowing their HIV status, 90% of people who know their HIV-positive status accessing treatment and 90% of people on treatment having suppressed viral loads by 2020.
Low vitamin D levels may hinder the efficacy of HIV treatment in adults, researchers from the University of Georgia reported.
Future study into IL-21 urged.
Molecule exposes latent HIV and broadly uses killer T cells to reduce HIV.
Fewer than half of patients with TFD-linked AKI had renal function recovery after drug withdrawal.
Medication contains a new form of tenofovir not previously approved by the FDA.
Statin use caused lower incidence of liver disease progression in HIV and HCV co-infected individuals.
According to a National Institutes of Health (NIH) Study, infants exposed in the womb to the HIV drug tenofovir disoproxil fumarate, may have lower bone mineral content than those exposed to other anti-HIV drugs.
The new guideline - released ahead of full publication later this year - notes that, in order to effectively implement the recommendations, countries will need to ensure that testing and treatment for HIV infection are readily available.
Seattle is a hub of infectious disease research.
The FDA has approved a pediatric labeling update for Reyataz (atazanavir) oral powder to include dosing recommendations for patients ≥3 months.
Sign Up for Free e-newsletters
Infectious Disease Advisor Articles
- Climate Change: Effects on the Incidence and Distribution of Infectious Diseases
- Improving Campaigns Regarding the Value of Adult Vaccines
- Seminal HPV Infection Prevalent Worldwide, May Affect Male Fertility
- Pausing ART to Identify Biomarkers for HIV RNA Rebound: Safety and Ethical Considerations
- MicroRNAs in Infectious Disease: Emerging Clinical Applications
- Efficacy of Direct-Acting Antivirals for HCV Clearance in Older Adults
- SVR Achieved With Sofosbuvir, Grazoprevir/Elbasvir Plus Ribavirin in HCV
- First Oral Smallpox Treatment Submitted to FDA for NDA
- Trends in Meningococcal Disease Following MenACWY Vaccine Introduction
- Clinician Accuracy Evaluated for Lyme Disease